| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
BERKELEY, Calif., November 5, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU) today reported financial results for the third quarter of 2026. |
| 06 Oct 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +2 more
— Company to evaluate strategic alternatives to maximize stockholder value — |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with... |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, Caribou Biosciences, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeti... |
| 11 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- |
| 31 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
BERKELEY, Calif., March 5, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 202... |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
BERKELEY, Calif., November 12, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the third quarter 2025 and p... |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
N O V E M B E R 3 , 2 0 2 5 Positive clinical updates on Caribou’s off-the-shelf CAR-T cell therapy programs: • Vispa-cel for r/r LBCL (vispacabtagene regedleucel; CB-010) • CB-011 for r/r MM 2 Caribou clinical data | November 3, 2025 ©2... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in |
| 23 Jun 2025 |
8-K: Other Events
On June 18, 2025, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), received a written notice (the “Compliance Notice”) from the Staff of the Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company has regained c... |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 12, 2025, Caribou Biosciences, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeti... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in |
| 24 Apr 2025 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities +1 more
-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- |
| 10 Mar 2025 |
8-K: Results of Operations and Financial Condition
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- |
| 13 Jan 2025 |
8-K: Regulation FD Disclosure
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 |
| 02 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
BERKELEY, Calif., January 2, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as chief financial off... |
| 06 Nov 2024 |
8-K: Results of Operations and Financial Condition
-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- |
| 03 Sep 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 1, 2024, Jason O’Byrne, the Chief Financial Officer of Caribou Biosciences, Inc. (the “Company”), informed the Company of his intent to resign from his position, effective September 27, 2024, to pursue another opportunity. M... |
Loading...